本研究係在探討藥用大麻對癲癇發作的控制之重要性，分析相關的藥用大麻醫療文獻、報導、研究和訪談。在病例的報告和臨床中顯示，天然的大麻素可以作用於降低人體神經元不正常放電的頻率。併用CBD與AEDs可以在癲癇發作方面發揮控制的作用。本研究以揭開大麻與癲癇之間的關係，促使在醫療上可以開放暨研究藥用大麻對癲癇患者的治療。

This study explores the importance of medicinal cannabis in the treatment of seizures and analyzes relevant medical marijuana publications, reports, research and interviews. According to several clinical studies, the use of CBD along with AEDs can effectively reduce the frequency of onsets of seizures. This study unveiled the relationship between cannabis and epilepsy, in hope to promote the use of medicinal cannabis in the treatment of patients with epilepsy.

中文文獻
中央社，2018。泰國批准大麻藥用和研究 東南亞首個合法化國家。https://www.cna.com.tw/news/firstnews/201812250372.aspx
中央社，2019。浩宇獲准頑性癲癇臨床試驗 預計第2季啟動 最新更新：2019/02/18 20:15 https://www.cna.com.tw/news/afe/201902180287.aspx
中央社，2019。菲律賓眾議院通過法案 准許大麻醫療使用。https://www.cna.com.tw/news/ahel/201901290317.aspx
公共政策網路參與平台，2017。將CBD(大麻二酚)列入巴金森氏症和癲癇病患醫療適應症之處方 https://join.gov.tw/idea/detail/44fcf089-c00a-41b4-9791-b816e67f88ee
台灣藥物臨床試驗資訊網，2010。 A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) in relieving pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. http://www1.cde.org.tw/ct_taiwan/search_case2.php
台灣癲癇醫學會，2003。92/09/04關於癲癇。http://www.epilepsy.org.tw/ContentAspx/ViewCotent.aspx?pk=003092200003&isClass=6
江志明、謝惟竣，2018。科學月刊。從古今歷史中認識大麻，第585期：678-681。
全國法規資料庫，2017。毒品危害防制條例, 修正日期：民國 106 年 06 月 14 日 https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=C0000008
社團法人台灣癲癇之友協會，2019。癲癇 -- 也是一種病症而已 http://www.epilepsyorg.org.tw/introduction/info.asp?/1.html
財團法人罕見疾病基金會，2018。《台灣卓飛協會成立大會》記者會。http://www.tfrd.org.tw/tfrd/library_e/content/id/154
陳亮妤，2018。科學月刊。吸食大麻後的如醉似幻－這是什麼癮頭？，第585期：682-685。
陳景宗，2018。科學月刊。探究大麻的生理機制與藥理應用，第585期：692-695。
陳慧慈，2018。大麻概念股開趴 投資人嗨翻天，財訊電子報: 2018-10-31 https://www.wealth.com.tw/home/articles/18367
雅虎新聞，2018。韓國大麻法修正：2019年開始醫療用大麻合法化！https://tw.news.yahoo.com/%E9%9F%93%E5%9C%8B%E5%A4%A7%E9%BA%BB%E6%B3%95%E4%BF%AE%E6%AD%A3-2019%E5%B9%B4%E9%96%8B%E5%A7%8B%E9%86%AB%E7%99%82%E7%94%A8%E5%A4%A7%E9%BA%BB%E5%90%88%E6%B3%95%E5%8C%96-005800969.html

董懷仁，2018。美國大麻產業現況分析及未來趨勢，國立臺灣範大學管理學院高階經理人企業管理碩士在職專班碩士論文。
維基百科，2019。大麻的合法性。 https://zh.wikipedia.org/wiki/%E5%A4%A7%E9%BA%BB%E7%9A%84%E5%90%88%E6%B3%95%E6%80%A7
衛生福利部國民健康署，2019。108 年 2 月罕見疾病通報個案統計表，108年2月：4。https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=3811&pid=10459

英文文獻
Allyn C. Howlett and Mary E. Abood, 2017. CB1 & CB2 Receptor Pharmacology, Adv Pharmacol. 2017; 80: 169–206. https://www.ncbi.nlm.nih.gov/pubmed/28826534
Andrew Hand, MSc, Alexia Blake, MSc, Paul Kerrigan, BSc, Phineas Samuel, Jeremy Friedberg, 2016. History of medical cannabis. J Pain Manage 2016;9(4):387-394. https://www.researchgate.net/publication/316545890_History_of_medical_cannabis
BCC Research LLC, 2018. Global Anti-Epileptic Drug Market to Reach $9.5 Billion by 2022, April 04, 2018, Anti-Epileptic Drugs: Global Markets to 2022( PHM197A ). https://www.bccresearch.com/pressroom/phm/global-anti-epileptic-drug-market-to-reach-$95-billion-by-2022
David Castle and Sanil Rege, 2018. The Psychopharmacology of Cannabis and its Impact on Mental Health – A Primer. Psychscenehub, Posted on September 25, 2018. https://psychscenehub.com/psychinsights/psychopharmacology-cannabis-and-mental-health/
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group, 2018. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631. https://www.nejm.org/doi/10.1056/NEJMoa1714631
Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE Part A Study Group., 2018. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018 Apr 3;90(14): e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14. https://n.neurology.org/content/90/14/e1204
Ethan B Russo, 2011. Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects, BJP Volume163, Issue7. https://scinapse.io/papers/2148841660
Ethan B. Russo, 2018. Cannabis Therapeutics and the Future of Neurology, Front Integr Neurosci. 2018; 12: 51, PMCID: PMC6200872, Published online 2018 Oct 18. doi: 10.3389/fnint.2018.00051, PMID: 30405366. https://www.frontiersin.org/articles/10.3389/fnint.2018.00051/full
EPIDIOLEX (cannabidiol), 2019. EPIDIOLEX® offers dosing flexibility to optimize treatment. https://www.epidiolexhcp.com/dosing-information
Globenewswire, 2018. GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006. February 21, 2018 16:01 ET | Source: GW Pharmaceuticals plc https://www.globenewswire.com/news-release/2018/02/21/1372900/0/en/GW-Pharmaceuticals-Announces-Preliminary-Results-of-Phase-2a-Study-for-its-Pipeline-Compound-GWP42006.html
GW Pharmaceuticals plc, 2018. EPIDIOLEX® (cannabidiol) Oral Solution – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S. Press Release, November 1, 2018 http://ir.gwpharm.com/news-releases/news-release-details/epidiolexr-cannabidiol-oral-solution-first-fda-approved-plant
GW Pharmaceuticals plc, 2018. GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce FDA Approval of EPIDIOLEX® (cannabidiol) oral solution – the First Plant-derived Cannabinoid Prescription Medicine, June 25, 2018. https://www.gwpharm.com/about/news/gw-pharmaceuticals-plc-and-its-us-subsidiary-greenwich-biosciences-announce-fda-approval
GW Pharmaceuticals plc Press Release, 2018. GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Quarter Ended December 31, 2018 http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-plc-reports-financial-results-and-operational
Incorpora G, 2009. Dravet syndrome. Ital J Pediatr. 2009 Sep 8;35(1):27. doi: 10.1186/1824-7288-35-27. https://www.ncbi.nlm.nih.gov/pubmed/19737414
Istok Nahtigal, Alexia Blake, Andrew Hand, Angelique Florentinus-Mefailoski, Haleh Hashemi and Jeremy Friedberg, 2016. The pharmacological properties of cannabis. J Pain Manage 2016;9(4):481-491 https://medreleafaustralia.com.au/wp-content/uploads/2017/11/2.The-pharmacological-properties-of-cannabis.pdf
Jahngir MU, Ahmad MQ, Jahangir M., 2018. Lennox-Gastaut Syndrome: In a Nutshell. Cureus. 2018 Aug 13;10(8): e3134. doi: 10.7759/cureus.3134. https://www.cureus.com/articles/14127-lennox-gastaut-syndrome-in-a-nutshell
Kunj Gohil, PharmD, RPh and Devin Enhoffer, PharmD, RPh, 2014. Modest Growth Seen in Epilepsy Market, NCBI, 2014 Nov; 39(11): 786–787. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218674/
Meir Bialer, Svein I. Johannessen, René H. Levy, Emilio Perucca, Torbjörn Tomson, H. Steve White, 2017. Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). First published: 23 January 2017. https://doi.org/10.1111/epi.13634.
Moran Hausman-kedem, Shay Menascu, Uri Kramer, 2018. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study. Article in Brain and Development 40(7) · April 2018 DOI: 10.1016/j.braindev.2018.03.013. https://www.brainanddevelopment.com/article/S0387-7604(18)30112-8/fulltext
Naomi Thomas, CNN, 2018. Are you heavier or shorter than the average American? Updated 1722 GMT (0122 HKT) December 20, 2018 https://edition.cnn.com/2018/12/20/health/us-average-height-weight-report/index.html
Natalya M. Kogan, Raphael Mechoulam, 2007. Cannabinoids in health and disease, Dialogues Clin Neurosci. 2007 Dec; 9(4): 413–430. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202504/
Orrin Devinsky, M.D., J. Helen Cross, Ph.D., F.R.C.P.C.H., Linda Laux, M.D., Eric Marsh, M.D., Ian Miller, M.D., Rima Nabbout, M.D., Ingrid E. Scheffer, M.B., B.S., Ph.D., Elizabeth A. Thiele, M.D., Ph.D., Stephen Wright, M.D., for the Cannabidiol in Dravet Syndrome Study Group, 2017. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. The new England journal of medicine, May 25, 2017 vol. 376 no. 21. https://www.nejm.org/doi/full/10.1056/nejmoa1611618
Peter Loftus, 2018. New Marijuana-Based Epilepsy Treatment to Cost $32,500 a Year - GW Pharmaceuticals CEO says the price was set to be in line with other brand-name epilepsy drugs. THE WALL STREET JOURNAL. Aug. 8, 2018 4:55 p.m. ET https://www.wsj.com/articles/new-marijuana-based-epilepsy-treatment-to-cost-32-500-a-year-1533761758
ProCon.org, 2013. 10 Pharmaceutical Drugs Based on Cannabis. Last updated on: 11/27/2013 10:44:40 AM PST https://medicalmarijuana.procon.org/view.resource.php?resourceID=000883
Profofpot, 2016. Trends in Clinical Trials of Medical Cannabis. Clinical Trial ReportsOctober 10, 2016Prof of Pot http://profofpot.com/clinical-trials-medical-cannabis-trends/
R G Pertwee, 2008. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin, Br J Pharmacol. 2008 Jan; 153(2): 199–215. https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0707442
Samir Chitnavis, 2019. GW PHARMACEUTICALS: CAMBRIDGE’S MARIJUANA POWERHOUSE. science-entrepreneur TECH SPOTLIGHT 4 FEBRUARY 2019 https://www.science-entrepreneur.com/blog-1/gw-pharmaceuticals
The Pharmaceutical Journal 2018. FDA grants first approval of a cannabis-derived medicine, Vol 301, No 7915, | DOI:10.1211/PJ.2018.20205071. https://www.pharmaceutical-journal.com/news-and-analysis/news/fda-grants-first-approval-of-a-cannabis-derived-medicine/20205071.article?firstPass=false
Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group, 2018. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Mar 17;391(10125):1085-1096. doi: 10.1016/S0140-6736(18)30136-3. Epub 2018 Jan 26. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30136-3/fulltext
Vinod K. Yaragudri, Editor, 2013. Modulation of the Endocannabinoids N-Arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on Executive Functions in Humans, PLoS One. 2013; 8(6): e66387. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066387